www.tonixpharma.com Open in urlscan Pro
162.241.142.33  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content

 * About
   * Leadership
     * Executive Team
     * Board of Directors
   * Facilities
 * Therapeutic Areas Overview
   * Central Nervous System
     * Fibromyalgia
     * Long COVID
     * Cocaine Intoxication
     * Migraine
   * Immunology
     * Organ Transplant Rejection
     * Gastro-Intestinal Cancers
   * Infectious Disease
     * Mpox (Monkeypox)
     * Smallpox
     * COVID-19
   * Rare Disease
     * Prader-Willi Syndrome
 * Pipeline
   * Central Nervous System
     * TNX-102 SL
     * TNX-1300
     * TNX-1900
   * Immunology
     * TNX-1500
     * TNX-1700
   * Infectious Disease
     * TNX-801
     * TNX-1800
     * Broad Spectrum Antivirals
   * Rare Disease
     * TNX-2900
   * Scientific Presentations
   * Expanded Access Policy
 * Medicines
 * Clinical Trials
 * News & Events
   * Tonix in the News
   * Press Releases
   * Investor Presentations
   * IR Events
   * Op-eds
 * Investors
   * News & Events
   * Presentations
   * Multimedia
   * Financial Info
   * Stock Data
   * SEC Filings
   * Governance
 * Careers
 * Contact Us


TONIX PHARMACEUTICALS AWARDED UP TO $34 MILLION U.S. DEPARTMENT OF DEFENSE
CONTRACT FOR ACCELERATED DEVELOPMENT OF BROAD-SPECTRUM ANTIVIRAL PROGRAM.




LATEST NEWS

July 25, 2024

Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for
Fibromyalgia

July 24, 2024

Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In
Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum
Antiviral

July 17, 2024

Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of
Fibromyalgia, is Planning Expected Launch in 2H 2025

July 10, 2024

Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering




ABOUT TONIX PHARMACEUTICALS



Tonix has a robust pipeline of programs in development stages ranging from
preclinical to preparing for NDA submission, across multiple therapeutic
modalities and including both small molecules and biologics. Tonix also markets
two FDA-approved products for acute migraine in adults.

Tonix’s pipeline is managed by a team of passionate professionals that are adept
at advancing innovative programs into the clinic and throughout the various
stages of development with the goal of FDA approval and marketing to those in
need.

While many of Tonix’s product candidates are proprietary, in-house developments,
it also has collaborations with government institutions, world-class academic
and non-profit research organizations, as well as license agreements with other
biotech companies.


LEARN MORE ABOUT US




THERAPEUTIC AREAS

Central Nervous System

Tonix is dedicated to finding cures for difficult to treat, widely occurring,
chronic disorders of the central nervous system including pain, neurological,
psychiatric and addiction conditions.* Our goal is to heal sufferings of
millions through scientific advancements.

Immunology

We are advancing scientific programs that focus on therapeutics to prevent organ
transplant rejection, to manage autoimmune conditions, and to improve responses
to immunotherapy in certain cancers.*

Infectious Disease

Tonix’s infectious disease portfolio targets pathogenic infections, including
monkeypox and smallpox for biodefense. Through its live virus vaccine platform
and in-house capabilities, Tonix strives to be prepared for future pandemics.

Rare Disease

Tonix is committed to improving patient care, including for those suffering from
rare diseases and for which no drug has been approved. Rare diseases are often
caused by genetic disorders and are characterized by complex symptoms. A rare
disease is a condition that affects fewer than 200,000 people in the US as
defined in the Orphan Drug Act of 1983.

CENTRAL NERVOUS SYSTEM

Tonix is dedicated to finding cures for difficult to treat, widely occurring,
chronic disorders of the central nervous system including pain, neurological,
psychiatric and addiction conditions.* Our goal is to heal sufferings of
millions through scientific advancements.

LEARN MORE

IMMUNOLOGY

We are advancing scientific programs that focus on therapeutics to prevent organ
transplant rejection, to manage autoimmune conditions, and to improve responses
to immunotherapy in certain cancers.*

LEARN MORE

INFECTIOUS DISEASE

Tonix’s infectious disease portfolio targets pathogenic infections, including
the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines,
antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to
combat infections like SARS-CoV-2.

LEARN MORE

RARE DISEASE

Tonix is committed to improving patient care, including for those suffering from
rare diseases and for which no drug has been approved. Rare diseases are often
caused by genetic disorders and are characterized by complex symptoms. A rare
disease is a condition that affects fewer than 200,000 people in the US as
defined in the Orphan Drug Act of 1983.

LEARN MORE



PIPELINE HIGHLIGHTS

Using our integrated clinical development engine, we advance innovative programs
into the clinic while maximizing asset potential.

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Fibromyalgia (FM)
Two statistically significant Phase 3 studies completed, expect to file NDA in
2nd Half 2024

Mid-Phase III

TNX-1300   Cocaine Intoxication / Overdose
Mid-Phase II — Breakthrough Therapy Designation

Mid-Phase II

TNX-1500   Organ Transplant Rejection / Autoimmune Disorders
Phase I — Clinical phase complete

Preclinical

VIEW OUR COMPLETE PIPELINE



MANAGEMENT TEAM

“Many frontiers remain in the fields of medical science and drug development. At
Tonix, we have carefully chosen pursuits in immunology, rare diseases,
infectious diseases, and central nervous system disorders. We are building
capabilities in synthetic biology, precision medicine, protein engineering, and
vaccine manufacturing to develop better and safer medicines. Our ultimate goals
are to improve and extend the lives of millions of people and, importantly, to
reward the dedication and commitment of our stakeholders.”
— Dr. Seth Lederman, M.D., President and CEO, Tonix Pharmaceuticals

MEET OUR TEAM


*ALL OF TONIX’S PRODUCT CANDIDATES ARE INVESTIGATIONAL NEW DRUGS OR BIOLOGICS
AND HAVE NOT BEEN APPROVED FOR ANY INDICATION.


Sign up for Email Alerts

 * Contact Us
 * Privacy Policy
 * Terms of Use
 * Site Map

© 2024 Tonix Pharmaceuticals Holding Corp.

Cookie Notification
We use 1st and 3rd party cookies to enhance your experience of our website, save
your preferences, and provide us with information on how you use our website.
For more information, please refer to our Privacy Policy. By accessing or using
our website, you consent to our use of cookies. You may opt out of the use of
cookies by adjusting your browser settings.

Accept